The Trump administration’s cuts to a global AIDS relief program threaten to upend rollout of a groundbreaking HIV prevention ...

PEPFAR had been set to lead the rollout of Gilead Science's lenacapavir, which has been hailed as a "miracle" of HIV ...

A groundbreaking Phase 1 study suggests that once-yearly intramuscular lenacapavir could be a promising option for HIV PrEP.

She’d acquired HIV as a college student in the 1980s, she told the audience at an infectious disease conference in San ...

News of potential federal budget cuts impacting HIV drugs in the U.S. was quickly reflected in a dip in share prices for top ...

Citigroup said it’s “very bullish” on Gilead’s HIV franchise, arguing it’s the drugmaker’s biggest value driver as the company’s new ...

The world risks returning to the worst days of the global AIDS pandemic following the sudden halt to US foreign aid funding, ...

Winnie Byanyima, head of UNAIDS, criticized the impact of reduced U.S. funding in combatting HIV. She proposed a deal to U.S.

UNAIDS Executive Director Winnie Byanyima said the sudden loss of American money has been 'devastating' for efforts to stop ...

By Gift BritonThe once-a-year injectable pre-exposure prophylaxis (PrEP), Lenacapavir, has shown promising results in a recent Phase 1 clinical trial.The trial involved 40 healthy adults aged between ...

A single shot of a new formulation of the antiretroviral drug lenacapavir could potentially provide protection against HIV infection for as long as a year. Spotlight reports on this and some of the ...